All Stories

  1. Long‐Term Use of Benzodiazepines and Related Drugs in Persons With Major Depressive Disorder
  2. Relapse risk prediction in patients with first-episode bipolar disorder: development, external validation, and pharmacotherapy associations of a machine learning model
  3. Psychopathic Traits Associate With Later Schizophrenia
  4. Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
  5. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders
  6. Metabolic Alterations in Human Post‐Mortem Frontal Cortex and Cerebrospinal Fluid Associated With High Levels of Nicotine Metabolite Cotinine
  7. Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
  8. Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized?
  9. miRNA profiling of hiPSC-derived neurons from monozygotic twins discordant for schizophrenia
  10. Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
  11. Metabolic alterations in human post-mortem frontal cortex and cerebrospinal fluid associated with high levels of nicotine metabolite cotinine
  12. The challenges of antipsychotic polypharmacy
  13. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk—Reply
  14. Labor market marginalization in individuals with bipolar disorder: a Swedish nationwide register-based sibling comparison study
  15. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
  16. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
  17. Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety
  18. Severe side effects of the most effective schizophrenia medication
  19. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia
  20. Association of obesity to reaction time and visual memory in schizophrenia
  21. Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up
  22. Aberrant type 2 dopamine receptor availability in violent offenders with psychopathy
  23. Astrocytes Regulate Neuronal Network Burst Frequency Through NMDA Receptors in a Species- and Donor-Specific Manner
  24. Cardiovascular mortality in bipolar disorder: Population‐based cohort study
  25. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case–control study in Finland
  26. Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts
  27. Medication use and sickness absence from work in bipolar disorder: a nationwide register‐based study
  28. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study
  29. Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia
  30. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study
  31. Development and Validation of a Machine Learning–Based Model of Mortality Risk in First-Episode Psychosis
  32. Navigated and individual α-peak-frequency–guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
  33. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
  34. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data
  35. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
  36. Long-term benzodiazepine use and risk of labor market marginalization in Finland: A cohort study with 5-year follow-up
  37. Effect of severity of depression on augmentation of antidepressant medication in young adults with depression
  38. Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
  39. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
  40. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
  41. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
  42. Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
  43. Cohort profile: SUPER-Finland – the Finnish study for hereditary mechanisms of psychotic disorders
  44. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
  45. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study
  46. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
  47. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
  48. Psychotic depression and deaths due to suicide
  49. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
  50. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  51. Factors and their weight in reducing life expectancy in schizophrenia
  52. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland
  53. Mortality in psychotic depression: 18-year follow-up study
  54. Twenty‐year medication use trends in first‐episode bipolar disorder
  55. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
  56. Mu-opioid receptor system modulates responses to vocal bonding and distress signals in humans
  57. Real‐world effectiveness of mood stabilizer use in schizophrenia
  58. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study
  59. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts
  60. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder
  61. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
  62. Clozapine and the risk of haematological malignancies – Authors' reply
  63. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study
  64. Real-world effectiveness studies of low doses of antipsychotics – Authors' reply
  65. Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study
  66. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
  67. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
  68. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland
  69. Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
  70. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
  71. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
  72. Aberrant motor contagion of emotions in psychopathy and high-functioning autism
  73. Female Psychopathy and Mortality
  74. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
  75. Clinical and societal burden of incident major depressive disorder: A population‐wide cohort study in Stockholm
  76. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
  77. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
  78. Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
  79. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  80. Brain structural alterations in autism and criminal psychopathy
  81. The iPSC perspective on schizophrenia
  82. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia
  83. Switches and early discontinuations of antidepressant medication in young adults with depression
  84. Exploring the relation between high-activity COMT Val158Met genotype and psychopathy in male offenders
  85. Correspondence regarding De Girolamo et al., 2021 ‘A multinational case–control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project’
  86. Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
  87. Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
  88. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
  89. Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder
  90. Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation
  91. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
  92. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
  93. Antipsychotic discontinuation: mind the patient and the real-world evidence
  94. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  95. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study
  96. Molecular signaling pathways underlying schizophrenia
  97. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
  98. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
  99. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry
  100. Brain Basis of Psychopathy in Criminal Offenders and General Population
  101. Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
  102. Registry-based studies: What they can tell us, and what they cannot
  103. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases
  104. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use
  105. Morbidity and mortality in schizophrenia with comorbid substance use disorders
  106. Voluntary patient safety incidents reporting in forensic psychiatry—What do the reports tell us?
  107. Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
  108. Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients
  109. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
  110. Risk of labour market marginalisation among young refugees and non-refugee migrants with common mental disorders
  111. Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
  112. Long-Term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  113. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
  114. Rejoinder to rejoinder to commentary
  115. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study
  116. Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
  117. Medication management of antipsychotic treatment in schizophrenia—A narrative review
  118. Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
  119. P.810Real-world effectiveness of mood stabilizer use in persons with schizophrenia
  120. Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
  121. Commentary on Robert Whitaker's viewpoint
  122. Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory
  123. Corrigendum to “Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour” [Behav. Brain Res. 382 (2020) 112476]
  124. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
  125. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
  126. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
  127. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
  128. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
  129. Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
  130. Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
  131. The clinical course of schizophrenia in women and men—a nation-wide cohort study
  132. T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
  133. Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour
  134. A Systematic Literature Review of Neuroimaging of Psychopathic Traits
  135. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
  136. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
  137. Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
  138. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
  139. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
  140. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
  141. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease
  142. Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
  143. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease
  144. Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study
  145. Correction: Neurobiological roots of psychopathy
  146. Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
  147. Sex-specific transcriptional and proteomic signatures in schizophrenia
  148. Neurobiological roots of psychopathy
  149. Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer’s disease
  150. Cortical structure abnormalities in females with conduct disorder prior to age 15
  151. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study
  152. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
  153. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease
  154. Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease
  155. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
  156. Increased [³H]quisqualic acid binding density in the dorsal striatum and anterior insula of alcoholics: A post-mortem whole-hemisphere autoradiography study
  157. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
  158. Changes in patient safety culture: A patient safety intervention for Finnish forensic psychiatric hospital staff
  159. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  160. Trajectories of sickness absence, disability pension and unemployment in young immigrants with common mental disorders
  161. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
  162. Incidence of head injury and traumatic brain injury among people with Alzheimer’s disease
  163. Manifesto for an international digital mental health network
  164. Risk of Treatment Failure: Response to Ghosh and Noble
  165. Associations of Psychopathic Traits With Local and Global Brain Network Topology in Young Adult Women
  166. Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  167. Concomitant use of benzodiazepines and opioids in community‐dwelling older people with or without Alzheimer's disease—A nationwide register‐based study in Finland
  168. Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
  169. Comorbid opioid use is undertreated among forensic patients with schizophrenia
  170. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease
  171. Incidence and prevalence of antiepileptic drugs use in persons with Alzheimer's disease.
  172. Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
  173. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study
  174. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease
  175. Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
  176. Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls
  177. Risk of Treatment Failure: Response to Czobor and Volavka
  178. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
  179. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  180. Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer’s Disease: Retrospective Register-Based Cohort Study
  181. Mortality in schizophrenia: 30‐year nationwide follow‐up study
  182. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
  183. Editorial: let's take a break from studying the PPI‐fracture association—Authors’ reply
  184. Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
  185. Cause-specific mortality in Finnish forensic psychiatric patients
  186. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
  187. Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
  188. Comparison of dispensed medications and forensic‐toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013
  189. Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data
  190. Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease
  191. Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
  192. Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
  193. Platelet monoamine oxidase activity and interpersonal violence in male suicide attempters
  194. Associations Between MAOA‐uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males
  195. Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder
  196. Firesetting and general criminal recidivism among a consecutive sample of Finnish pretrial male firesetters: A register-based follow-up study
  197. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
  198. Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior
  199. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
  200. Risk of disability pension in first and second generation immigrants: the role of age and region of birth in a prospective population-based study from Sweden
  201. Healthcare use among immigrants and natives in Sweden on disability pension, before and after changes of regulations
  202. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study
  203. Nurses’ Views Highlight a Need for the Systematic Development of Patient Safety Culture in Forensic Psychiatry Nursing
  204. De‐escalation techniques used, and reasons for seclusion and restraint, in a forensic psychiatric hospital
  205. Drug exposure in register-based research—An expert-opinion based evaluation of methods
  206. Trajectories and characteristics of work disability before and after acute myocardial infarction
  207. Use of lithium in patients with unipolar depression – Author's reply
  208. Is Alzheimer’s Disease Associated with Previous Opioid Use?
  209. Effects of Scheduled Waiting for Psychotherapy in Patients With Major Depression
  210. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations
  211. Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
  212. The Association of Ambient Temperature and Violent Crime
  213. White matter correlates of psychopathic traits in a female community sample
  214. Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence
  215. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study
  216. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
  217. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease
  218. Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study
  219. Psychopathy and Mortality
  220. Screening approach for identifying candidate drugs and drug‐drug interactions related to hip fracture risk in persons with Alzheimer disease
  221. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer’s Disease
  222. Seasonal variation of hospital violence, seclusion and restraint in a forensic psychiatric hospital
  223. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer’s disease
  224. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  225. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study
  226. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease
  227. Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
  228. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease
  229. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study
  230. Antidepressant use and risk of hip fractures among community‐dwelling persons with and without Alzheimer's disease
  231. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease
  232. Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease
  233. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
  234. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease
  235. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland
  236. Differences in analgesic use in community‐dwelling persons with and without Alzheimer's disease
  237. Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer’s Disease
  238. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study
  239. Real‐world effectiveness of antipsychotics
  240. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics
  241. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
  242. The effects of a HTR2B stop codon and testosterone on energy metabolism and beta cell function among antisocial Finnish males
  243. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders
  244. Drug use in persons with and without Alzheimer's disease aged 90 years or more
  245. Genome-wide association study of antisocial personality disorder
  246. Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men
  247. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
  248. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
  249. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics
  250. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
  251. Nurses' Time Use in Forensic Psychiatry
  252. Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
  253. Incidence of antidepressant use in community‐dwelling persons with and without Alzheimer's disease: 13‐year follow‐up
  254. Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment
  255. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon
  256. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort
  257. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
  258. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies
  259. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease
  260. Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
  261. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
  262. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression
  263. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study
  264. Hospital-treated suicide attempts among Finnish fire setters: a follow-up study
  265. Opioid abuse and hospitalization rates in patients with schizophrenia
  266. A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life
  267. Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study
  268. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease
  269. Factors Associated with Hospitalization for Blood-Borne Viral Infections Among Treatment-Seeking Illicit Drug Users
  270. Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland
  271. Psychotropic drugs and homicide: A prospective cohort study from Finland
  272. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland
  273. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
  274. Psychopathic traits among a consecutive sample of Finnish pretrial fire-setting offenders
  275. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  276. Characteristics of drug-abusing females with and without children seeking treatment in Helsinki, Finland
  277. Basal insulin secretion, PCL-R and recidivism among impulsive violent alcoholic offenders
  278. Mortality of firesetters: A follow-up study of Finnish male firesetters who underwent a pretrial forensic examination in 1973–1998
  279. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study
  280. Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
  281. Increased Metabotropic Glutamate 2/3 Receptor Binding in the Perigenual Anterior Cingulate Cortex of Cloninger Type 2 Alcoholics: A Whole-Hemisphere Autoradiography Study
  282. Antipsychotic Treatment and Mortality in Schizophrenia
  283. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
  284. Patterns and 14-year trends in mortality among illicit drug users in Finland: The HUUTI study
  285. Genetic background of extreme violent behavior
  286. Lower [3H]Citalopram Binding in Brain Areas Related to Social Cognition in Alcoholics
  287. Corrigendum to “Mortality among clients seeking treatment for buprenorphine abuse in Finland” [Drug Alcohol Depend. 133 (2013) 391–397]
  288. Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
  289. Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease
  290. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
  291. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
  292. Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
  293. Mortality among forensic psychiatric patients in Finland
  294. Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland
  295. Metacognitive group training for forensic and dangerous non‐forensic patients with schizophrenia: A randomised controlled feasibility trial
  296. AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  297. Mortality among clients seeking treatment for buprenorphine abuse in Finland
  298. Patient Safety Culture in Two Finnish State-Run Forensic Psychiatric Hospitals
  299. Previous forensic mental examination is a useful marker indicating effective violence relapse prevention among psychotic patients
  300. Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
  301. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
  302. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics
  303. Cavum septum pellucidum and psychopathy
  304. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis
  305. mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study
  306. Violent behaviour in a forensic psychiatric hospital in Finland: an analysis of violence incident reports
  307. Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: The HUUTI study
  308. Clozapine resistance—Augmentation strategies
  309. Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle
  310. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics
  311. Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
  312. Word List Learning in Patients with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
  313. Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval
  314. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation
  315. Using the HCR-20 to Predict Aggressive Behavior among Men with Schizophrenia Living in the Community: Accuracy of Prediction, General and Forensic Settings, and Dynamic Risk Factors
  316. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland
  317. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial
  318. Ketamine in treatment-resistant major depression
  319. Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial
  320. Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence
  321. Sociodemographic Characteristics and Drug Abuse Patterns of Treatment-Seeking Illicit Drug Abusers in Finland, 1997–2008: The Huuti Study
  322. Description of long-term polypharmacy among schizophrenia outpatients
  323. Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
  324. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
  325. Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia
  326. Whole-hemisphere autoradiography of 5-HT1B receptor densities in postmortem alcoholic brains
  327. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
  328. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
  329. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
  330. Reply to Drs. Nauta and van Domburg
  331. Examining the effectiveness of antipsychotic medication in first-episode psychosis
  332. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
  333. The Substance Use among Forensic Psychiatric Patients
  334. The net effect of smoking on healthcare and welfare costs. A cohort study
  335. Toward Molecular Psychotherapy of Depression?
  336. The Patient–Therapist Interaction and the Recognition of Affects during the Process of Psychodynamic Psychotherapy for Depression
  337. Statin usage and all‐cause and disease‐specific mortality in a nationwide study
  338. Erratum: Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  339. The place of observational studies in assessing the effectiveness of depot antipsychotics
  340. Cortex and amygdala morphology in psychopathy
  341. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
  342. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
  343. Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
  344. Interrelationship between core interventions and core competencies of forensic psychiatric nursing in Finland
  345. Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions
  346. Psychopathic brain -- an unknown challenge for treatment
  347. Gender differences in brain serotonin transporter availability in panic disorder
  348. Group psychoeducation for long‐term offender patients with schizophrenia: An exploratory randomised controlled trial
  349. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
  350. Serotonin‐transporter‐linked promoter region polymorphism and serotonin transporter binding in drug‐naïve patients with major depression
  351. Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
  352. MAOA Alters the Effects of Heavy Drinking and Childhood Physical Abuse on Risk for Severe Impulsive Acts of Violence Among Alcoholic Violent Offenders
  353. Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics
  354. EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES
  355. The Intergenerational Cycle of Criminality—Association with Psychopathy*
  356. Seasonal variation of seclusion incidents from violent and suicidal acts in forensic psychiatric patients
  357. Dopamine transporter binding in females with panic disorder may vary with clinical status
  358. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach
  359. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
  360. Mortality in patients with schizophrenia – Author's reply
  361. Incidence of cancer and antidepressant medication: Record linkage study
  362. Incidence of cancer and statin usage—Record linkage study
  363. Cardiac repolarization and striatal dopamine transporter function are interrelated
  364. Abnormal hippocampal shape in offenders with psychopathy
  365. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
  366. Dopamine D2/3receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
  367. Abnormal Cortical Morphology in Offenders with Psychopathy
  368. Low non-oxidative glucose metabolism and violent offending: An 8-year prospective follow-up study
  369. Recidivistic offending and mortality in alcoholic violent offenders: A prospective follow-up study
  370. Altered hemispheric balance of temporal cortex dopamine D2/3 receptor binding in major depressive disorder
  371. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts.
  372. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
  373. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort
  374. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
  375. Effects of MAOA‐Genotype, Alcohol Consumption, and Aging on Violent Behavior
  376. 5-HT1A Receptors in the Frontal Cortical Brain Areas in Cloninger Type 1 and 2 Alcoholics Measured by Whole-Hemisphere Autoradiography
  377. Pharmacotherapy of Methamphetamine Addiction: An Update
  378. Brain anatomy of persistent violent offenders: More rather than less
  379. Midbrain serotonin and striatum dopamine transporter binding in double depression: A one-year follow-up study
  380. Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food
  381. Predicting Forensic Admission among the Mentally Ill: A Bayesian Approach
  382. Temporal cortex dopamine D2/3 receptor binding in major depression
  383. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
  384. Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
  385. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  386. Characterization of metabolic syndrome among forensic psychiatric inpatients
  387. Antidepressant use and mortality in Finland: A register-linkage study from a nationwide cohort
  388. Cortical dopamine D1 receptors in type 1 and type 2 alcoholics measured with human whole hemisphere autoradiography
  389. Changes in midbrain serotonin transporter availability in atypically depressed subjects after oneyear of psychotherapy
  390. Correlation between the SERT binding densities in hypothalamus and amygdala in cloninger type 1 and 2 alcoholics
  391. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
  392. Body size and violent offending among males in the Northern Finland 1966 birth cohort
  393. Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography
  394. A Comparison of General Adult and Forensic Patients with Schizophrenia Living in the Community
  395. Energy substrate metabolism among habitually violent alcoholic offenders having antisocial personality disorder
  396. Real-world effectiveness of pharmacological treatments in schizophrenia
  397. Violent persons with schizophrenia and comorbid disorders: A functional magnetic resonance imaging study
  398. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging
  399. A Multisite Study of Community Treatment Programs for Mentally Ill Offenders With Major Mental Disorders
  400. Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study
  401. Transmission of violent offending and crime across three generations
  402. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  403. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  404. Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort
  405. Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography
  406. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography
  407. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
  408. Midbrain binding of [123I]nor-β-CIT in atypical depression
  409. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
  410. Midbrain dopamine D2/3 receptor binding in schizophrenia
  411. Glutamatergic drugs for schizophrenia
  412. Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
  413. P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort
  414. Lower serotonin transporter binding in caudate in alcoholics
  415. Seasonal variations in [3H]citalopram platelet binding between healthy controls and violent offenders in Finland
  416. The consequences of Conduct Disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services
  417. Premorbid Intellectual Functioning in Bipolar Disorder and Schizophrenia: Results From a Cohort Study of Male Conscripts
  418. Topiramate Add-On in Treatment-Resistant Schizophrenia
  419. Subcritical water as eluent for chromatographic separation of carbohydrates using cation-exchange resins
  420. Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography
  421. Effects of Venlafaxine Treatment on Clozapine Plasma Levels in Schizophrenic Patients
  422. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
  423. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  424. An Outcome of Psychodynamic Psychotherapy: A Case Study of the Change in Serotonin Transporter Binding and the Activation of the Dream Screen
  425. Dopamine and alcoholism: neurobiological basis of ethanol abuse
  426. Reduced brain serotonin transporter binding in patients with panic disorder
  427. A controlled study of tryptophan and cortisol in violent offenders
  428. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder
  429. Cortical dopamine D2receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  430. Elevated midbrain serotonin transporter availability in mixed mania: a case report
  431. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using []SB-269970
  432. THE MEDIAL TEMPORAL LOBE IN ALCOHOLISM AND PSYCHOPATHOLOGY: EVALUATION BY VOLUMETRIC MRI.
  433. MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia
  434. 123I-?-CIT binding and recovery from depression
  435. Brain serotonin 1A receptor binding in bulimia nervosa
  436. Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia
  437. Comorbid Personality Disorders and Substance Use Disorders of Mentally Ill Homicide Offenders: A Structured Clinical Study on Dual and Triple Diagnoses
  438. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
  439. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients
  440. Treatment improves serotonin transporter binding and reduces binge eating
  441. P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder
  442. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  443. Total plasma l‐tryptophan, free l‐tryptophan and competing amino acid levels in a homicidal male adolescent with conduct disorder
  444. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆
  445. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males
  446. Different effect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics
  447. Alcoholics show altered histaminergic neurotransmission in several cortical areas - Preliminary report
  448. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients
  449. Co-eluent effect in partition chromatography. Rhamnose–xylose separation with strong and weak cation-exchangers in aqueous ethanol
  450. Seasonal variation in specific methods of suicide: a national register study of 20 234 Finnish people
  451. Glutamatergic drugs for schizophrenia
  452. Is occupation relevant in suicide?
  453. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism
  454. Use of Statistical Techniques in Studies of Suicide Seasonality, 1970 to 1997
  455. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia
  456. The quantitative risk of violent crime and criminal offending: a case‐control study among the offspring of recidivistic Finnish homicide offenders
  457. Effect of alcohol abuse on human brain histamine and tele-methylhistamine
  458. Serotonin Transporter Distribution and Density in the Cerebral Cortex of Alcoholic and Nonalcoholic Comparison Subjects: A Whole-Hemisphere Autoradiography Study
  459. Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics
  460. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder
  461. Seclusion treatment measures and serum cholesterol levels among Finnish male forensic psychiatric patients
  462. Serum lipid levels and violence among Finnish male forensic psychiatric patients
  463. Impaired Temporal Lobe Processing of Preattentive Auditory Discrimination in Schizophrenia
  464. Dopamine Transporter Density and Novelty Seeking Among Alcoholics
  465. Mortality of antisocial male criminals
  466. Free L -tryptophan plasma levels in antisocial violent offenders
  467. Recidivism Among Serious Violent Crime Offenders in Finland
  468. SPECT and neuropsychological performance in severe depression treated with ECT
  469. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography
  470. Altered frontal lobe function suggested by source analysis of event-related potentials in impulsive violent alcoholics
  471. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  472. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  473. Reduced serotonin transporter binding in binge eating women
  474. Effects of ageing on serotonin transporters in healthy females
  475. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naı̈ve schizophrenia
  476. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics
  477. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics
  478. Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression
  479. Mortality of antisocial male criminals
  480. Psychopathy and the posterior hippocampus
  481. Characterization of γ-aminobutyrate type A receptors with atypical coupling between agonist and convulsant binding sites in discrete brain regions
  482. In vivo voltammetry with removable carbon fibre electrodes in freely-moving mice: dopamine release during intracranial self-stimulation
  483. Recidivistic Violent Behavior and Axis I and Axis II Disorders
  484. Patterns of dopamine overflow in mouse nucleus accumbens during intracranial self-stimulation
  485. S19.03 Spet studies on outcome of treatment by psychosocial interventions in depression and hysterical paresthesia
  486. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients
  487. Forensic Psychiatric Organization in Finland
  488. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
  489. Ethanol modulates evoked dopamine release in mouse nucleus accumbens: dependence on social stress and dose
  490. Regional cerebral blood flow during exposure to food in obese binge eating women
  491. CYP2A6 genotype and smoking
  492. A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism
  493. Metabolism of [ 123 I]epidepride may affect brain dopamine D 2 receptor imaging with single-photon emission tomography
  494. Association Between the Functional Polymorphism of Catechol‐O‐Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  495. Association Between the Functional Polymorphism of Catechol-O-Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  496. Pharmacological Intervention for Preventing Violence Among the Mentally Ill with Secondary Alcohol-And Drug-Use Disorders
  497. Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior
  498. Reversed Hemispheric Asymmetry of Auditory N100m in Schizophrenics
  499. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics
  500. Quantitative MRI of the hippocampus and amygdala in severe depression
  501. Dopamine transporter and D 2 -receptor density in late-onset alcoholism
  502. Erratum to “Mortality among habitually violent offenders”
  503. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
  504. Transient Syncope and ECG Changes Associated With the Concurrent Administration of Clozapine and Diazepam
  505. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14 182 patients
  506. Pindolol and Major Affective Disorders
  507. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
  508. Striatal dopamine transporter density in major depression
  509. Dopamine transporter availability and depressive symptoms during alcohol withdrawal
  510. Maternal Smoking During Pregnancy and Risk of Criminal Behavior Among Adult Male Offspring in the Northern Finland 1966 Birth Cohort
  511. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism
  512. Serum testosterone levels, mental disorders and criminal behaviour
  513. Reply
  514. Mortality among habitually violent offenders
  515. Is a Large Body Size During Childhood a Risk Factor for Later Aggression?
  516. Comparison of Iodine-123 Labelled Nor-β-CIT and β-CIT as Potential Radioligands for Serotonin Transporter Imaging
  517. Schizophrenia and seasonality of admissions: the Northern Finland 1966 birth cohort study
  518. Altered Parallel Auditory Processing in Schizophrenia Patients
  519. Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957–95
  520. Chronic pindolol treatment and major affective disorders
  521. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis
  522. 83 Altered frontal lobe function suggested by erp generator analysis in impulsive violent alcoholics
  523. Fentanyl decreases ?-CIT binding to the dopamine transporter
  524. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation
  525. Seasonal variation in suicide occurrence in Finland
  526. Secular trends in the rates and seasonality of violent and nonviolent suicide occurrences in Finland during 1980–95
  527. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
  528. Resersal of cerebral asymmetry in schizophrenia measured with magnetoencephalography
  529. The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
  530. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography
  531. The incidence and onset-age of hospitalized bipolar affective disorder in Finland
  532. Schizophrenia, alcohol abuse and violent behaviour
  533. Change in monoamine transporter density related to clinical recovery: A case-control study
  534. Fractal analysis – a new approach in brain receptor imaging
  535. Juvenile mortality, mental disturbances and criminality: a prospective study of the Northern Finland 1966 birth cohort
  536. Parental age gap and child sex ratio—Fact or fiction?
  537. Schizophrenia, Alcohol Abuse, and Violent Behavior: A 26-Year Followup Study of an Unselected Birth Cohort
  538. Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
  539. Seasonal Variation in the Occurrence of Homicide in Finland
  540. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour
  541. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis
  542. Fractal analysis of striatal dopamine re-uptake sites
  543. Fractal analysis of striatal dopamine re-uptake sites
  544. Seasonal variation of homicide occurrence in Finland
  545. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort
  546. Striatal and extrastriatal imaging of dopamine D 2 receptors in the living human brain with [ 123 I]epidepride single-photon emission tomography
  547. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography
  548. Dopamine reuptake site densities in patients with social phobia
  549. Schizophrenia, alcohol abuse and violent behaviour
  550. Psychiatric disorders and violent behavior
  551. The predictors of schizophrenia in the 1966 Northern Finland birth cobort study
  552. Impaired adaptation to external input in impulsive violent alcoholics
  553. Characterization of C-11 or I-123 Labelled β-CIT‐FP and β-CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  554. Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  555. Forensic psychotherapy
  556. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography
  557. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
  558. Mental Disorders and Homicidal Behavior in Finland
  559. Risk of homicidal behavior among discharged forensic psychiatric patients
  560. Factors associated with homicide recidivism in a 13-year sample of homicide offenders in Finland
  561. Low incidence of mania in northern Finland
  562. Schizophrenia and Homicidal Behavior
  563. Citalopram in the Treatment of Alcoholism: a Double-blind Placebo-controlled Study
  564. Quantitative Risk Assessment of Homicidal Behaviour
  565. Homicidal behaviour and mental disorders
  566. The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method
  567. Drs. Tiihonen and Kuikka Reply
  568. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics
  569. Iodine-123 labelledN-(2-fluoroethyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
  570. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
  571. Imaging of serotonin and dopamine transporters in the living human brain
  572. Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter
  573. Risk of homicidal behaviour among persons convicted of homicide
  574. Altered cerebral blood flow during hysterical paresthesia
  575. Carbamazepine-induced Changes in Plasma Levels of Neuroleptics
  576. Increase in cerebral blood flow of right prefrontal cortex in man during orgasm
  577. Eltoprazine for aggression in schizophrenia and mental retardation
  578. Long-Term Effects of Bilateral Frontal Lobe Lesions from Neuropsychiatric and Neuroradiological Aspects
  579. Magnetoencephalographic localization of epileptic cortex—impact on surgical treatment
  580. Fast decrement with stimulus repetition in ERPs generated by neuronal systems involving somatosensory SI and SII cortices: Electric and magnetic evoked response recordings in humans
  581. Neuromagnetic mismatch fields to single and paired tones
  582. Eosinophilia associated with clozapine
  583. Magnetoencephalographic 10-Hz rhythm from the human auditory cortex
  584. Reply
  585. Localization of epileptic foci using a large‐area magnetometer and functional brain anatomy
  586. Separate finger representations at the human second somatosensory cortex
  587. Early deflections of cerebral magnetic responses to median nerve stimulation
  588. Evoked responses of human auditory cortex may be enhanced by preceding stimuli
  589. Multichannel detection of magnetic compound action fields of median and ulnar nerves
  590. Paired Tone Presentation Enhances Responses of Human Auditory Cortex to Rare Frequency Changes
  591. Magnetic mu rhythm in man
  592. Evoked and Spontaneous Magnetic Activity of the Human Somatosensory Cortex
  593. Molecular characterization of a Y;15 translocation segregating in a family